Stock Events

Stock Events

Recce Pharmaceuticals 

A$0.5
5
+A$0+0% Today

Statistics

Day High
0.5
Day Low
0.49
52W High
0.73
52W Low
0.28
Volume
10,515
Avg. Volume
103,546
Mkt Cap
143.15M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27FebExpected
Q4 2022
Q2 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
-0.06
-0.05
-0.04
-0.03
Expected EPS
N/A
Actual EPS
-0.053728815345699836

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-42.86MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RCE.AU. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap153.13B
Pfizer is a global pharmaceutical company that competes with Recce Pharmaceuticals in the development and commercialization of antibiotics and treatments for infectious diseases.
Merck
MRK
Mkt Cap300.2B
Merck & Co., Inc. is involved in the discovery, development, manufacturing, and marketing of pharmaceuticals, including therapies for infectious diseases, directly competing with Recce Pharmaceuticals' focus areas.
GSK
GSK
Mkt Cap116.3B
GlaxoSmithKline plc engages in the creation and marketing of vaccines and medications for infections, competing in the same space as Recce Pharmaceuticals.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie operates in the pharmaceuticals sector, focusing on advanced therapies, including treatments for infectious diseases, which puts it in competition with Recce Pharmaceuticals.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson, through its pharmaceutical segment, develops treatments for infectious diseases among other areas, competing with Recce Pharmaceuticals.
Astrazeneca
AZN
Mkt Cap316.3B
AstraZeneca PLC works on the development of drugs for various diseases, including infections, making it a competitor to Recce Pharmaceuticals.
Novartis
NVS
Mkt Cap297.35B
Novartis AG focuses on innovative medicines, including anti-infectives, which competes with Recce Pharmaceuticals' research and development in antibiotics.
Sanofi
SNY
Mkt Cap113.88B
Sanofi focuses on healthcare solutions, including antibiotics and treatments for infectious diseases, competing with Recce Pharmaceuticals.
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Bristol Myers Squibb is involved in the discovery, development, and delivery of medicines, including those for infectious diseases, competing with Recce Pharmaceuticals.
AMGEN
AMGN
Mkt Cap189.22B
Amgen Inc. focuses on human therapeutics, including treatments for infections, though its main focus is on biologics, it competes in the broader pharmaceuticals market with Recce Pharmaceuticals.

About

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase I/II clinical trials for topical wound infections and diabetic foot infections. The company has strategic partnership with Murdoch Children's Research Institute for development of the Acinetobacter baumannii and Mycobacterium abscessus; and cooperative research and development agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to be tested against highly hazardous pathogens. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Show more...
CEO
Dr. John K. A. Prendergast Ph.D.
Country
Australia
ISIN
AU000000RCE5

Listings

F
DE
R9Q.F
STU
DE
R9Q.STU
MU
DE
R9Q.MU
OTC Link
US
RECEF

0 Comments

Share your thoughts

FAQ

What is Recce Pharmaceuticals stock price today?▼
The current price of RCE.AU is A$0.5 AUD — it has increased by +0% in the past 24 hours. Watch Recce Pharmaceuticals stock price performance more closely on the chart.
What is Recce Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Recce Pharmaceuticals stocks are traded under the ticker RCE.AU.
Is Recce Pharmaceuticals stock price growing?▼
RCE.AU stock has risen by +9.89% compared to the previous week, the month change is a +5.26% rise, over the last year Recce Pharmaceuticals has showed a +66.67% increase.
What is Recce Pharmaceuticals market cap?▼
Today Recce Pharmaceuticals has the market capitalization of 143.15M
When is the next Recce Pharmaceuticals earnings date?▼
Recce Pharmaceuticals is going to release the next earnings report on August 28, 2026.
What were Recce Pharmaceuticals earnings last quarter?▼
RCE.AU earnings for the last quarter are -0.05 AUD per share, whereas the estimation was N/A AUD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A AUD per share.
What is Recce Pharmaceuticals revenue for the last year?▼
Recce Pharmaceuticals revenue for the last year amounts to 0 AUD.
What is Recce Pharmaceuticals net income for the last year?▼
RCE.AU net income for the last year is -42.86M AUD.
In which sector is Recce Pharmaceuticals located?▼
Recce Pharmaceuticals operates in the Health & Wellness sector.
When did Recce Pharmaceuticals complete a stock split?▼
Recce Pharmaceuticals has not had any recent stock splits.
Where is Recce Pharmaceuticals headquartered?▼
Recce Pharmaceuticals is headquartered in Sydney, Australia.